Last update 30 Mar 2025

68Ga-NOTA-GUL

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms
68Ga-GUL-SCN-NOTA, 68Ga-NGUL, Gallium-68-GUL-SCN-NOTA
+ [4]
Target
PSMA
Action
modulators
Mechanism
PSMA modulators(Prostate-specific membrane antigen modulators)
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication
Metastatic castration-resistant prostate cancer
Inactive Indication-
Originator Organization
Cellbion Co., Ltd.Cellbion Co., Ltd.
Active Organization
Cellbion Co., Ltd.Cellbion Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with 68Ga-NOTA-GUL
NCT05547061
/ Active, not recruitingPhase 1/2
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
100 Clinical Results associated with 68Ga-NOTA-GUL
Login to view more data
100 Translational Medicine associated with 68Ga-NOTA-GUL
Login to view more data
100 Patents (Medical) associated with 68Ga-NOTA-GUL
Login to view more data
100 Deals associated with 68Ga-NOTA-GUL
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Castration-Resistant Prostatic CancerPhase 2
South Korea
Cellbion Co., Ltd.Cellbion Co., Ltd.
30 Apr 2021
Metastatic castration-resistant prostate cancerPhase 2
South Korea
Cellbion Co., Ltd.Cellbion Co., Ltd.
12 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASCO_GU2018
Not Applicable
Recurrent Prostate Carcinoma
121
(PSMA-RGS)
wuuhwsetud(duzztzvrpz) = Eleven pts suffered from Clavien grade III complications within 90d from surgery jrzovhmlkd (pinmwkechc )
View more
Positive
26 Feb 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free